Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.

ABSTRACT:

Background

Pharmacogenetics is involved in customizing therapy according to the genetic makeup of an individual, and is applicable for chemotherapy, radiotherapy as well as targeted therapy. Drug metabolizing enzymes (DMEs) involving both phase I, and phase II reactions are widely studied. Our study was involved in whole exome sequencing (WES) of cancer patients, followed by analysis for identifying key variations in DMEs, and associated transporters that have a potential impact on treatment outcome.

Methodology

A total of 181 solid tumor patients at stage >/= III were subjected to WES by the SureSelect^XT Human All Exon V6 + UTR library preparation kit, and sequencing in the Illumina NextSeq 550 system. Bioinformatics analysis involved use of GATK pipeline, and th

SUBMITTER: Aboul-Soud MAM 

PROVIDER: S-EPMC7783809 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature